Kiyoto Tsuchiya

发表

Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.

H. Jono, T. Shinohara, K. Tsuchiya, 2013, Biochemical and biophysical research communications.

Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity.

W. Sugiura, S. Oka, H. Ode, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

S. Matsushita, S. Oka, T. Koike, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

S. Oka, N. Tachikawa, T. Shirasaka, 2004, Biochemical and biophysical research communications.

Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors

S. Oka, H. Gatanaga, Y. Kikuchi, 2017, PloS one.

A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

Kwang Su Kim, S. Matsushita, H. Mitsuya, 2019, Cell reports methods.

Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.

S. Oka, K. Higasa, H. Gatanaga, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

N-(4-Hydroxyphenyl) Retinamide Suppresses SARS-CoV-2 Spike Protein-Mediated Cell-Cell Fusion by a Dihydroceramide Δ4-Desaturase 1-Independent Mechanism

J. Gohda, K. Maeda, A. Yamashita, 2021, Journal of virology.

N-(4-Hydroxyphenyl)retinamide suppresses SARS-CoV-2 spike protein-mediated cell-cell fusion and viral infection in vitro

J. Gohda, K. Maeda, A. Yamashita, 2021 .

Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19

M. Sugiyama, M. Mizokami, T. Kano, 2020, Gene.

A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators

H. Mitsuya, K. Maeda, R. Kariya, 2021, Frontiers in Microbiology.

Sphingomyelin Synthase 2, but Not Sphingomyelin Synthase 1, Is Involved in HIV-1 Envelope-mediated Membrane Fusion*

A. Yamashita, T. Sugiura, Y. Hayashi, 2014, The Journal of Biological Chemistry.

Emergence of Protease Inhibitor Resistance–Associated Mutations in Plasma HIV-1 Precedes That in Proviruses of Peripheral Blood Mononuclear Cells by More Than a Year

S. Oka, H. Gatanaga, K. Tsuchiya, 2003, Journal of acquired immune deficiency syndromes.

Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variants

S. Oka, Y. Takamatsu, S. Kutsuna, 2023, Scientific Reports.

Low Raltegravir Concentration in Cerebrospinal Fluid in Patients With ABCG2 Genetic Variants

S. Oka, H. Gatanaga, Tsunefusa Hayashida, 2014, Journal of acquired immune deficiency syndromes.

A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

Kwang Su Kim, S. Matsushita, H. Mitsuya, 2021, Cell reports methods.

The WIPE assay for selection and elimination of HIV-1 provirus in vitro using latency-reversing agents

S. Matsushita, H. Mitsuya, S. Oka, 2019, bioRxiv.

A widely-distributed HIV-1 provirus elimination assay to evaluate 2 latency-reversing agents in vitro 3

Kosaku Kitagawa, S. Islam, S. Hattori, 2022 .

Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro

H. Mitsuya, S. Oka, K. Maeda, 2018, Front. Microbiol..

High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples.

S. Oka, H. Gatanaga, K. Tsuchiya, 2018, Biomedical chromatography : BMC.

Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.

H. Mitsuya, K. Maeda, K. Tsuchiya, 2008, Journal of molecular biology.

Full‐genome analysis of hepatitis C virus in HIV‐coinfected hemophiliac Japanese patients

S. Oka, M. Sugiyama, M. Mizokami, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Brief Report: High Peak Level of Plasma Raltegravir Concentration in Patients With ABCB1 and ABCG2 Genetic Variants

S. Oka, H. Gatanaga, Tsunefusa Hayashida, 2016, Journal of acquired immune deficiency syndromes.

Allele and Genotype Frequencies of Cytochrome P450 2B6 Gene in a Mongolian Population

S. Oka, H. Gatanaga, Tsunefusa Hayashida, 2009, Drug Metabolism and Disposition.

Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort.

S. Oka, N. Tachikawa, K. Teruya, 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Protein Arginine N-methyltransferases 5 and 7 Promote HIV-1 Production

M. Takei, Y. Aida, M. Taura, 2020, Viruses.